Proteomics in drug development
Pharma-led proteomics initiatives
The importance of proteomics for future drug development is exemplified in the UK Biobank Pharma Proteomics Project (UKB-PPP), where a consortium of 13 leading pharma companies funded a project to measure ~1500 proteins in over 53,000 individuals with the goal of better understanding of disease biology and more effective therapies. Recently published early findings reported over 10,000 primary genetic associations with plasma protein levels (pQTLs), 85% of which are novel findings. Read more about this and other collaborative initiatives aimed towards future drug development in our blog post.
Proteomics to accelerate successful drug development - key applications
Save time/cost/inconvenience of invasive sampling (tissue biopsies, imaging etc)
Reduce the size and cost of clinical trials by identifying likely responders during selection of enrollees
Characterize mode of drug action through deep understanding of disease biology
New applications through deeper understanding of disease patho-mechanisms
Proteomics & multiomic studies will revolutionize future drug development
Proteomics at the heart of multiomics strategies
Systems biology approaches addressing multiple molecular and cellular components are adding vital insights into the dynamic biology underlying human health and disease.
Hear from industry experts on how proteomics is changing the way we develop new drugs and study disease.
The power of proteomics in multiomic studies
Download the eBook, ‘Proteomics at the heart of multiomic studies’ to learn more about how this trend is the next step in advancing precision medicine.
Protein data points generated
Publications listed on website